| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
1 company
Freeman Kevin D is a Director at GALT. Recent filings cover 30 purchases and 0 sales. Those positions are worth an estimated $191K at current prices.
Our model assigns Freeman Kevin D a middling insider score of 57/100, based on 17 past trades. Over a 12-month horizon, 43.8% of those trades were profitable, with an average 12-month return of +1.5%.
Freeman Kevin D's largest disclosed position is in GALT as Director, worth about $191K. Net of sales, the recent Form 4 record there shows accumulation of 119,309 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Nov 15, 2019 | GALT Galectin Therapeutics Inc | Director | Buy | 3,000 | $3.36 | $10,075.80 | +27.3% | |
| Sep 6, 2019 | GALT Galectin Therapeutics Inc | Director | Buy | 1,290 | $3.71 | $4,785.90 | +13.3% | |
| May 31, 2019 | GALT Galectin Therapeutics Inc | Director | Buy | 9,136 | $4.28 | $39,102.08 | +38.0% | |
| Apr 5, 2019 | GALT Galectin Therapeutics Inc | Director | Buy | 500 | $4.73 | $2,365.00 | +33.3% | |
| Feb 8, 2019 | GALT Galectin Therapeutics Inc | Director | Buy | 1,500 | $4.29 | $6,427.50 | New | |
| Feb 1, 2018 | GALT Galectin Therapeutics Inc | Director | Buy | 2,000 | $4.10 | $8,191.00 | +14.3% | |
| Feb 1, 2018 | GALT Galectin Therapeutics Inc | Director | Buy | 2,000 | $4.10 | $8,191.00 | +14.3% | |
| Jun 1, 2015 | GALT Galectin Therapeutics Inc | Director | Buy | 2,083 | $2.70 | $5,624.10 | New |